Kidney Week

Oral Abstract Session

Glomerular Disease Outcomes: Measuring What Matters

November 07, 2025 | 04:30 PM - 06:00 PM

Location: Room 310A, Convention Center

Session Description

Oral Abstract Session

Note: Continuing education credits are not being offered for this session.

Learning Pathway(s)

• Glomerular Diseases

Moderators

• Pietro A. Canetta, MD, MS, FASN
• Yelena Drexler, MD, MS, FASN

Presentations

• Impact of Polygenic Scores on Kidney Failure Risk Prediction Models in IgAN
  04:30 PM - 04:40 PM
  
  • Yan Ouyang, PhD

Impact of Polygenic Scores on Kidney Failure Risk Prediction Models in IgAN

November 07, 2025 | 04:30 PM - 04:40 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• US Patients with IgAN and Low Proteinuria Have Significantly Better Kidney Survival than Participants in the UK RADAR Study
  04:40 PM - 04:50 PM
  
  • Nilang G. Patel, MD, MS, FASN

US Patients with IgAN and Low Proteinuria Have Significantly Better Kidney Survival than Participants in the UK RADAR Study

November 07, 2025 | 04:40 PM - 04:50 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Glomerular Disease Outcomes Across the Lifespan: Report of the Cure Glomerulonephropathy (CureGN) Research Consortium
  04:50 PM - 05:00 PM
  
  • Margaret Helmuth, MA

Glomerular Disease Outcomes Across the Lifespan: Report of the Cure Glomerulonephropathy (CureGN) Research Consortium

November 07, 2025 | 04:50 PM - 05:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Estimating the Benefits of Proteinuria Reduction on Kidney Failure Risk in the DUPLEX Study Using an Aligned FSGS Cohort from the UK RaDaR Registry
  05:00 PM - 05:10 PM
  
  • Alex Mercer, PhD

Estimating the Benefits of Proteinuria Reduction on Kidney Failure Risk in the DUPLEX Study Using an Aligned FSGS Cohort from the UK RaDaR Registry

November 07, 2025 | 05:00 PM - 05:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Impact of Histology on Efficacy of Sparsentan Therapy in IgAN: Central Biopsy Review of Patients in the PROTECT Trial
  05:10 PM - 05:20 PM
  
  • Ian Roberts, MBChB

Impact of Histology on Efficacy of Sparsentan Therapy in IgAN: Central Biopsy Review of Patients in the PROTECT Trial

November 07, 2025 | 05:10 PM - 05:20 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Whole-Blood RNA Sequencing (RNAseq) Profiling Identifies Functionally Enriched Gene Expression Patterns in Felzartamab-Treated Patients with IgAN: Data from the Phase 2 IGNAZ Study
  05:20 PM - 05:30 PM
  
  • Millie Shah, PhD

Whole-Blood RNA Sequencing (RNAseq) Profiling Identifies Functionally Enriched Gene Expression Patterns in Felzartamab-Treated Patients with IgAN: Data from the Phase 2 IGNAZ Study

November 07, 2025 | 05:20 PM - 05:30 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Efficacy and Safety of Atrasentan in Patients (Pts) with IgAN from East (E) Asia: Phase 3 ALIGN Interim Data
  05:30 PM - 05:40 PM
  
  • Hong Zhang, MD, PhD

Efficacy and Safety of Atrasentan in Patients (Pts) with IgAN from East (E) Asia: Phase 3 ALIGN Interim Data

November 07, 2025 | 05:30 PM - 05:40 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Safety and Preliminary Efficacy of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
  05:40 PM - 05:50 PM
  
  • Samir V. Parikh, MD, FASN

Safety and Preliminary Efficacy of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis

November 07, 2025 | 05:40 PM - 05:50 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Exosome-Derived TMEM106A Participates in Podocyte Injury via EGR1 in Preeclampsia
  05:50 PM - 06:00 PM
  
  • Jinxiu Hu

Exosome-Derived TMEM106A Participates in Podocyte Injury via EGR1 in Preeclampsia

November 07, 2025 | 05:50 PM - 06:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.